Nucala (mepolizumab) for the Treatment of Hypereosinophilic Syndrome (HES)

The US FDA approved Nucala for the treatment of HES in September 2020. Credit: GlaxoSmithKline.



  • Nucala (mepolizumab)
  • Nucala (mepolizumab)
  • Nucala (mepolizumab)